The cost-effectiveness of the treatment of high risk women with osteoporosis, hypertension and hyperlipidaemia in Sweden

Osteoporosis International

Volumn 19, Issue 6, 2008, Pages 819-827

  Zethraeus, N ^a   Strom O ^b   Borgstrom F ^b,c   Kanis, J A ^d   Jonsson B ^a  

^a STOCKHOLM SCHOOL OF ECONOMICS   (Sweden)

^b European Health Economics   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

^d UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Bisphosphonates; Cost; Hydrochlorthiazides; QALY; Statins

Indexed keywords

ALENDRONIC ACID; HYDROCHLOROTHIAZIDE; SIMVASTATIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HIGH RISK POPULATION; HIP FRACTURE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; OSTEOPOROSIS; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY ADJUSTED LIFE YEAR; SWEDEN; VERTEBRA FRACTURE; WOMEN'S HEALTH; WRIST FRACTURE;

AGED; AGED, 80 AND OVER; ALENDRONATE; ANTIHYPERTENSIVE AGENTS; BONE DENSITY CONSERVATION AGENTS; COST-BENEFIT ANALYSIS; FEMALE; HEALTH CARE COSTS; HUMANS; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; HYPERTENSION; MIDDLE AGED; MODELS, ECONOMETRIC; OSTEOPOROSIS, POSTMENOPAUSAL; QUALITY-ADJUSTED LIFE YEARS; SIMVASTATIN; SWEDEN;

EID: 43249112837     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-007-0511-0     Document Type: Article

References (39)

1. Zethraeus N, Borgstrom F, Strom O, Kanis JA et al (2007) Cost-effectiveness of the treatment and prevention of osteoporosis-a review of the literature and a reference model. Osteoporos Int 18:9-23
2. Zethraeus N, Ben Sedrine W, Caulin F, Corcaud S et al (2002) Models for assessing the cost-effectiveness of the treatment and prevention of osteoporosis. Osteoporos Int 13:841-857
3. Fleurence RL, Iglesias CP, Torgerson DJ (2006) Economic evaluations of interventions for the prevention and treatment of osteoporosis: a structured review of the literature. Osteoporos Int 17:29-40
4. Anderson GL, Limacher M, Assaf AR, Bassford T et al (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 291:1701-1712
5. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ et al (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288:321-333
6. Zethraeus N, Borgstrom F, Jonsson B, Kanis J (2005) Reassessment of the cost-effectiveness of hormone replacement therapy in Sweden: results based on the Women's Health Initiative randomized controlled trial. Int J Technol Assess Health Care 21:433-441
7. Zethraeus N, Borgström F, Jönsson B, Kanis J (2004) A reassessment of the cost-effectiveness of hormone replacement therapy in Sweden - results based on the Women's Health Initiative randomised controlled trial. Working Paper Series in Economics and Finance at the Stockholm School of Economics, 2004, Working paper No 571 http://swopec.hhs.se/hastef/papers/ hastef0571.pdf
8. Stevenson M, Jones ML, Davis S, Beverly C (2005) Extract from DSU report: Osteoporosis - primary prevention. http://wwwniceorguk/pageaspx?o=273738
9. Black DM, Schwartz AV, Ensrud KE, Cauley JA et al (2006) Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296:2927-2938
10. Greenspan SL, Emkey RD, Bone HG, Weiss SR et al (2002) Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 137:875-883
11. Shepherd J, Cobbe SM, Ford I, Isles CG et al (2004) Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. 1995. Atheroscler Suppl 5:91-97
12. Hebert PR, Moser M, Mayer J, Glynn RJ et al (1993) Recent evidence on drug therapy of mild to moderate hypertension and decreased risk of coronary heart disease. Arch Intern Med 153:578-581
13. SBU (1994) [The Swedish Council on Technology Assessment in Health Care]. Moderately elevated blood pressure. Report No 121. Stockholm
14. SBU (2004) [The Swedish Council on Technology Assessment in Health Care]. Moderately elevated blood pressure - a systematic review. Report No 170. Stockholm
15. Johannesson M (2001) At what coronary risk level is it cost-effective to initiate cholesterol lowering drug treatment in primary prevention? Eur Heart J 22:919-925
16. Johannesson M, Hedbrant J, Jonsson B (1991) A computer simulation model for cost-effectiveness analysis of cardiovascular disease prevention. Med Inform (Lond) 16:355-362
17. Jönsson B, Hedbrant J, Johnell O (1993) A computer simulation model to analyse the cost-effectiveness of fracture prevention of osteoporosis. EFI Research paper Nr 6525
18. Borgstrom F, Zethraeus N, Johnell O, Lidgren L et al (2006) Costs and quality of life associated with osteoporosis-related fractures in Sweden. Osteoporos Int 17:637-650
19. Strom O, Borgstrom F, Zethraeus N, Johnell O et al (2007) Long term costs and quality of life associated with osteoporosis related fractures in Sweden. accepted in Acta Orthopaedica (September)
20. Wolf PA, D'Agostino RB, Belanger AJ, Kannel WB (1991) Probability of stroke: a risk profile from the Framingham Study. Stroke 22:312-318
21. Wilson PW, D'Agostino RB, Levy D, Belanger AM et al (1998) Prediction of coronary heart disease using risk factor categories. Circulation 97:1837-1847
22. Hellenius M, Rosell M, Sandgren J (2000) High prevalence of overweight and metabolic syndrome among 60 year old women and men in Stockholm, Sweden. 12th International Symposium on Atherosclerosis Stockholm
23. Kanis JA, Johnell O, Oden A, Jonsson B et al (2000) Risk of hip fracture derived from relative risks: an analysis applied to the population of Sweden. Osteoporos Int 11:120-127
24. De Laet CE, van Hout BA, Burger H, Hofman A et al (1997) Bone density and risk of hip fracture in men and women: cross sectional analysis. BMJ 315:221-225
25. Kanis JA, Johnell O, De Laet C, Johansson H et al (2004) A meta-analysis of previous fracture and subsequent fracture risk. Bone 35:375-382
26. Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA 3rd, et al (2000) Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 15:721-739
27. Chobanian AV, Bakris GL, Black HR, Cushman WC et al (2003) Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42:1206-1252
28. NCEP (2002) Third report of the National Cholesterol Education Program. Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 106:3143-3421
29. WHO (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO Study Group. World Health Organ Tech Rep Ser 843:1-129
30. FASS för förskrivare. Accessed [2006-11-24] http://www.fass.se
31. Hirth RA, Chernew ME, Miller E, Fendrick AM et al (2000) Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Making 20:332-342
32. Meltzer D (1997) Accounting for future costs in medical cost-effectiveness analysis. J Health Econ 16:33-64
33. Johannesson M, Meltzer D, O'Conor RM (1997) Incorporating future costs in medical cost-effectiveness analysis: implications for the cost-effectiveness of the treatment of hypertension. Med Decis Making 17:382-389
34. Johannesson M, Jonsson B, Kjekshus J, Olsson AG et al (1997) Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group. N Engl J Med 336:332-336
35. SBU (2003) [The Swedish Council on Technology Assessment in Health Care]. Osteoporosis - prevention, diagnosis and treatment. Report No 165. Stockholm
36. Strom O, Borgstrom F, Sen SS, Boonen S et al (2007) Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries-an economic evaluation based on the fracture intervention trial. Osteoporos Int 18:1047-1061
37. Borgstrom F, Carlsson A, Sintonen H, Boonen S et al (2006) The cost-effectiveness of risedronate in the treatment of osteoporosis: an international perspective. Osteoporos Int 17:996-1007
38. Stevenson M, Lloyd Jones M, De Nigris E, Brewer N et al (2005) A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. Health Technol Assess 9:1-160
39. Kanis JA, Johnell O, Oden A, Sembo I et al (2000) Long-term risk of osteoporotic fracture in Malmo. Osteoporos Int 11:669-674